Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:25:58 EDT Mon 12 Oct 2026
Enter Symbol
or Name
USA
CA



Q:FATE - FATE THERAPEUTICS - https://www.fatetherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FATE - Q0.11.96·2.192.12.18+0.052.3773.51,4924,1842.13  2.275  2.103.23  0.9519:30:04Oct 0215 min RT 2¢

Recent Trades - Last 10 of 4184
Time ETExPriceChangeVolume
19:30:04Q2.170.041
18:45:48Q2.170.041,500
18:43:59Q2.17030.04031,222
17:22:52Q2.170.0450
16:26:37Q2.170.0446
16:10:04Q2.180.051
16:03:48Q2.210.081
16:00:20Q2.180.05100
16:00:19Q2.180.0521
16:00:17Q2.180.051

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-10-02 07:00U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 07:00U:FATENews ReleaseFate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
2026-09-25 07:00U:FATENews ReleaseFate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
2026-09-16 07:00U:FATENews ReleaseFate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
2026-09-09 07:00U:FATENews ReleaseFate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 Meeting
2026-09-03 07:00U:FATENews ReleaseFate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
2026-08-14 07:00U:FATENews ReleaseFate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
2026-08-13 08:30U:FATENews ReleaseFate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
2026-08-03 16:05U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-07-09 08:30U:FATENews ReleaseFate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
2026-07-06 08:30U:FATENews ReleaseFate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
2026-07-01 16:05U:FATENews ReleaseFate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
2026-06-15 08:30U:FATENews ReleaseFate Therapeutics Appoints Laura Hamill to Board of Directors
2026-06-12 08:10U:FATENews ReleaseAfter CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
2026-06-08 09:01U:FATENews ReleaseThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
2026-06-04 08:30U:FATENews ReleaseFate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
2026-06-02 16:05U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 08:30U:FATENews ReleaseFate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
2026-05-21 08:30U:FATENews ReleaseFate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
2026-05-13 08:30U:FATENews ReleaseFate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates